Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Vercauteren, D. Strasser, E. Vezzali, A. Stalder, M. Iglarz, P. Hess, M. Clozel (Allschwil, Switzerland). Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists. Eur Respir J 2012; 40: Suppl. 56, 3898

Member's Comments

No comment yet.

Related content which might interest you: The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010 Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001 Evaluation of a selective 5-hydroxytryptamine 2B receptor antagonist designed to alter the fibrotic process Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007 In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407 Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007 Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006 Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005 Modulation of cortical and respiratory activity by 5-HT2 receptor agonist in the rat Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008 Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019 The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A (NKA)-induced bronchoconstriction in patients with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 415s Year: 2003 Ligand independent activation of the glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2004; 24: Suppl. 48, 317s Year: 2004 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006 Effect of long-acting β2 adrenergic receptor agonists and glucocorticoids on extracellular matrix production Source: Eur Respir J 2001; 18: Suppl. 33, 475s Year: 2001 Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020 Year: 2020